All Trials

A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/metastatic NSCLC harboring protocol-defined MET alterations (e.g., MET exon 14 skipping and/or MET amplification), ECOG 0–1, adequate organ function, and no untreated/active CNS disease are treated with REGN5093 (davutamig) monotherapy. REGN5093 is an investigational biparatopic/bispecific anti-MET monoclonal antibody that binds two MET epitopes to promote MET internalization/degradation and suppress MET-driven signaling, given in dose escalation followed by expansion at selected dose(s).

ClinicalTrials.gov ID: NCT04077099

Assessing the Impact of Circadian Rhythm on Anti-PD-1/PD-L1 Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic cancers—especially first-line NSCLC (including maintenance after induction) and other solid tumors—who are receiving FDA on-label PD-1/PD-L1 immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, atezolizumab, durvalumab; agents that block PD-1/PD-L1 signaling to restore T-cell antitumor activity) alone or with other approved therapies. Patients are randomized to receive each ICI dose on an early schedule (completed by 11:00 AM) versus a late schedule (start after 12:00 PM) to assess differences in outcomes and toxicity.

ClinicalTrials.gov ID: NCT07224971

Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with first platinum-sensitive recurrent high-grade serous (or predominantly serous) ovarian, fallopian tube, or primary peritoneal cancer who have achieved PR/CR after platinum-based chemotherapy plus bevacizumab and are continuing maintenance bevacizumab (typically enrolled 3–8 weeks after last chemo; ECOG 0–2; known BRCA/HRD status; generally not PARP maintenance candidates). Treatment adds oral hydroxychloroquine (late-stage autophagy inhibitor via lysosomal impairment) plus oral nelfinavir (HIV protease inhibitor that induces ER stress/UPR and may perturb autophagy) to standard bevacizumab 15 mg/kg IV q3w as maintenance.

ClinicalTrials.gov ID: NCT06971744

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with measurable metastatic or recurrent pancreatic adenocarcinoma (ECOG 0–1) who have not received prior systemic therapy for metastatic disease (adjuvant/neoadjuvant allowed if completed ≥12 months prior) and have adequate organ function. Treatment is first-line nivolumab (anti–PD-1) plus gemcitabine/nab-paclitaxel with added BMS-986340 (imzokitug), an investigational nonfucosylated anti-CCR8 IgG1 designed to block CCR8 and deplete CCR8+ tumor-infiltrating Tregs via ADCC, given in 28-day cycles until progression/toxicity (up to 2 years).

ClinicalTrials.gov ID: NCT07226856

A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 metastatic pancreatic ductal adenocarcinoma who have a documented SWI/SNF chromatin-remodeling gene alteration (e.g., ARID1A/ARID1B, PBRM1, SMARCA4, SMARCB1) and have received exactly one prior systemic line for metastatic disease and are immunotherapy-naïve. Patients receive cemiplimab (anti–PD-1 checkpoint inhibitor) plus gemcitabine chemotherapy until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT06790602

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-sensitive prostate adenocarcinoma on ADT for 6–12 months plus an AR pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide) for ≥4 months who have castrate testosterone but suboptimal PSA response (PSA ≥0.2 ng/mL) and no radiographic/clinical progression are randomized to continue ADT+ARPI versus add docetaxel IV chemotherapy (a taxane microtubule stabilizer that also disrupts androgen receptor trafficking/signaling). Key exclusions include prior taxane therapy, early castration-resistant PSA rise pattern, and significant neuropathy or hypersensitivity to polysorbate 80 formulations.

ClinicalTrials.gov ID: NCT06592924

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with castration-sensitive prostate adenocarcinoma and rising PSA who have de novo oligometastatic or hormone-sensitive oligoprogressive disease limited to ≤5 extrapelvic metastases on baseline PSMA-PET (no brain/liver mets) and are candidates for ablative-intent metastasis-directed radiotherapy to all sites (with primary controlled or treated). Patients receive stereotactic/ablative RT with cohort-based systemic therapy options (ADT ± an androgen receptor signaling inhibitor, or RT alone if declining systemic therapy), with serial flotufolastat F 18 PSMA-PET and ctDNA used to monitor response and detect progression.

ClinicalTrials.gov ID: NCT07210086

URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with recurrent or metastatic, measurable pleomorphic liposarcoma, PEComa, epithelioid sarcoma, CIC-rearranged sarcoma, or sclerosing epithelioid fibrosarcoma/low-grade fibromyxoid sarcoma who have progressed after their most recent therapy (ECOG 0–1; 1–3 prior systemic lines allowed; treated/stable brain metastases allowed; no prior PD-1/PD-L1/PD-L2 therapy). Single-arm cohorts receive pembrolizumab IV every 6 weeks, an anti–PD-1 monoclonal antibody checkpoint inhibitor that blocks PD-1/PD-L1/PD-L2 interactions to restore antitumor T-cell activity.

ClinicalTrials.gov ID: NCT07089992

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with radiographically confirmed intact brain metastasis 2–5 cm (KPS ≥60), neurologically stable, MRI-eligible, and lesions ≥5 mm from the optic apparatus; up to two large lesions may be treated (with up to 10 additional <2 cm metastases allowed for concurrent single-fraction SRS). Patients are randomized to staged SRS 24–30 Gy in 2 fractions with the second fraction ~30 days later versus FSRT 27 Gy in 3 daily fractions over 3–5 days (with concurrent single-fraction SRS for smaller lesions as needed).

ClinicalTrials.gov ID: NCT07227610

A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (≥18) with solid tumors and at least one intact/residual/recurrent “volatile” brain metastasis at higher risk for interval change/displacement (e.g., rapid growth, near edema or recent surgical cavity), KPS ≥60 and expected survival ≥3–6 months, are treated with same-day MRI-simulated, adaptively planned LINAC-based stereotactic radiosurgery/radiotherapy. Patients are randomized to stereotactic radiation using a 0 mm versus 1 mm planning target volume margin to test whether tighter margins can maintain control while reducing geographic miss and toxicity (e.g., radiation necrosis).

ClinicalTrials.gov ID: NCT07132190